Avanafil CAS330784-47-9 erection Treating erectile dysfunction in men Male aphrodisiac health materials

Drug information.

Chinese name: Avanafil.

Chinese alias: 4 - [(4 - methoxy 3 - chloro - benzyl) amino] - 2 - [2 - (hydroxymethyl) - 1 - pyrrole alkyl] - N - (2 - pyrimidine base methyl) - 5 - pyrimidine a sulfonamide

English nickname :4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl] -n -(2-Pyrimidinylmethyl) -5-Pyrimidinecarbox amide; (S)-2-(2-Hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[(2-pyrimidinylmethyl)carbamoyl]pyrimidine; 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carbo xamide

CAS number :330784-47-9

Molecular formula :C23H26ClN7O3

Molecular weight :483.9506

Molecular structure: Density :1.373g/cm

This phase II clinical study is folded and edited.

Tanabe's avanafil(Ⅰ) is effective in patients with erectile dysfunction (ED), according to the results of a multicenter Phase II study. 284 patients were given (Ⅰ)50, 100, 200, or 300mg or placebo 30 minutes before attempting sexual intercourse for 12 weeks. Rates of vaginal penetration were 76%, 79%, 80%, and 84%, respectively, when (Ⅰ)50, 100, 200, and 300mg were used to achieve adequate erections compared with placebo (p < 0.001). In addition, the rates of erections lasting long enough to successfully complete intercourse were 54 percent, 59 percent, 62 percent and 64 percent, respectively.

. Folding and editing this phase III clinical study.

The Phase III trial enrolled 646 patients with varying degrees of ED. The experiment was double-blind, placebo-controlled and randomized. Patients first went through a 4-week non-therapeutic run-in period and then received three doses of Avanafil (50mg, 100mg, and 200mf) for 12 weeks.

In the study, ED symptoms improved at the primary end point, as measured by sexual contact (SEP) and the International Erectile Function Index (IIEF). At the secondary end point, patients were also satisfied with erectile improvement and sex life.

In the study, patients who took Avanafil 15 minutes earlier had 64%, 67% and 71% success rates compared with the three doses, compared with 27% in the placebo group. The results showed that all three doses of Avanafil were superior to placebo at the terminal point. After 12 weeks of treatment, patients no longer overeat and drink to drown their sorrows. Avanafil is now under review by the FDA and is one step away from being marketed.